文献速递药物相互作用抗栓抗凝管理药物不良反应与药物警戒

新西兰罗红霉素增强华法林作用的病例系列分析

Case Series Analysis of New Zealand Reports of Rapid Intense Potentiation of Warfarin by Roxithromycin.
PubMed 文献 · Drug Saf · 2018-01-01

急性多药合用和严重感染可能促进了华法林增强作用并增加了相互作用的临床意义。

要点

  • 罗红霉素可使华法林抗凝作用迅速增强,INR显著升高,需密切监测。
  • 急性感染和多药合用(包括潜在相互作用药物)可能增加出血风险。
  • 华法林与罗红霉素的相互作用报告比例高于其他大环内酯类,临床应警惕。

核心结论

  • 在新西兰病例系列中,急性多药合用(包括潜在相互作用药物)和严重感染的普遍存在提示它们可能促进了华法林增强作用,并增加了罗红霉素/华法林相互作用的临床意义。

主要发现

  • 患者年龄范围23-88岁,平均66.8岁,中位数73.0岁(标准差17.7)。
  • 罗红霉素开始后国际标准化比值(INR)范围为3.6-16.7(平均7.6,中位数7.6,标准差3.6)。
  • 8例患者在第三天有测量值,INR为4.3-16.7(平均10.4,中位数8.8,标准差4.4)。
  • 4例患者发生严重出血。
  • 严重感染发生于54.5%(22例有信息患者中的12例),长期多药合用(每日五种或以上药物)占36.7%,急性期增至83.3%。

关键数值与推荐

  • 华法林每日剂量范围为1.5-13.0 mg(平均4.4,中位数4.0,标准差2.2)。
  • 罗红霉素前INR范围为1.4-3.7,平均和中位数均为2.5(标准差0.5)。

临床怎么用

  • 临床在罗红霉素与华法林合用时,应密切监测INR,尤其对于急性感染、多药合用、肾功能不全、高龄或华法林敏感性增加的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We undertook an analysis of all the reports to the New Zealand Centre for Adverse Reactions Monitoring of a roxithromycin/warfarin interaction after two recent reports described intense rapid warfarin potentiation. The interaction was first published in 1995. Cytochrome P450 3A4 inhibition has been the proposed mechanism but has limited biologic plausibility. There are suggestions that the clinical significance of the interaction may be increased by severe illness, polypharmacy, renal dysfunction, older age and increased warfarin sensitivity. METHODS: To investigate the potentiating effect of warfarin on roxithromycin in this New Zealand case series, the reports were reviewed to identify patients at risk, compare the reporting pattern with published Australian data and evaluate the appropriateness of current prescribing advice. RESULTS: Thirty patient reports were identified. The age range was 23-88 years, mean 66.8, median 73.0 (standard deviation 17.7) and the international normalised ratios after roxithromycin commencement ranged from 3.6 to 16.7 (mean 7.6, median 7.6, standard deviation 3.6). For eight patients with measurements on day 3, international normalised ratios were 4.3-16.7 (mean 10.4, median 8.8, standard deviation 4.4). Four patients had serious haemorrhage. Indications for roxithromycin were a range of respiratory tract infections. Anticoagulation was stable for most patients prior to acute infection. Serious infection occurred in 54.5% (12 of 22 patients with information). Polypharmacy (five or more medicines daily) was used by 36.7% of patients long term, increasing acutely to 83.3%, including additional potentially interacting medicines. Warfarin daily dose (1.5-13.0 mg, mean 4.4, median 4.0, standard deviation 2.2) was moderate to low. Pre-roxithromycin international normalised ratio values ranged from 1.4 to 3.7, mean and median 2.5, standard deviation 0.5. A high proportion of interactions were observed between warfarin and roxithromycin compared with other macrolides and compared with cytochrome P450 3A4-related macrolide interactions. The pattern was similar to published Australian data. CONCLUSION: In this case series, the high prevalence of acute polypharmacy, including potentially interacting medicines, and serious infection suggests that they may have contributed to warfarin potentiation and increased the clinical significance of a roxithromycin/warfarin interaction.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Savage RL, Tatley MV. Case Series Analysis of New Zealand Reports of Rapid Intense Potentiation of Warfarin by Roxithromycin. Drug Saf. 2018. PMID: 29330715. doi:10.1007/s40264-017-0634-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。